Review
doi: 10.1016/s0033-0620(05)80041-6.
Cost-effectiveness analysis in heart disease, Part I: General principles
Affiliations
- PMID: 7972851
- DOI: 10.1016/s0033-0620(05)80041-6
Item in Clipboard
Review
Cost-effectiveness analysis in heart disease, Part I: General principles
Prog Cardiovasc Dis.
1994 Nov-Dec.
No abstract available
Similar articles
-
Cost-effectiveness ratios: in a league of their own.Health Policy. 1994 May;28(2):133-41. doi: 10.1016/0168-8510(94)90031-0. Health Policy. 1994. PMID: 10136058 Review.
-
On the decision rules of cost-effectiveness analysis.J Health Econ. 1993 Dec;12(4):459-67. doi: 10.1016/0167-6296(93)90005-y. J Health Econ. 1993. PMID: 10131756 No abstract available.
-
The future of health economic modeling: have we gone too far or not far enough?Value Health. 2006 May-Jun;9(3):179-80. doi: 10.1111/j.1524-4733.2006.00115.x. Value Health. 2006. PMID: 16689711 No abstract available.
-
Bringing health economic modeling to the 21st century.Value Health. 2006 May-Jun;9(3):168-78. doi: 10.1111/j.1524-4733.2006.00097.x. Value Health. 2006. PMID: 16689710 No abstract available.
-
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?J Health Econ. 1992 Oct;11(3):279-96. doi: 10.1016/0167-6296(92)90004-k. J Health Econ. 1992. PMID: 10122540 Review.
Cited by
-
Economic analysis including long-term risks and costs of alternative diagnostic strategies to evaluate patients with chest pain.Cardiovasc Ultrasound. 2008 May 29;6:21. doi: 10.1186/1476-7120-6-21. Cardiovasc Ultrasound. 2008. PMID: 18510723 Free PMC article.
-
Cost efficiency of nuclear cardiology services in the modern health care environment.Curr Cardiol Rep. 2004 Jan;6(1):41-52. doi: 10.1007/s11886-004-0064-1. Curr Cardiol Rep. 2004. PMID: 14662097 Review.
-
A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.Eur J Health Econ. 2022 Dec;23(9):1577-1590. doi: 10.1007/s10198-022-01445-x. Epub 2022 Mar 2. Eur J Health Econ. 2022. PMID: 35235078
-
Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.Pharmacoeconomics. 1999 Jan;15(1):47-74. doi: 10.2165/00019053-199915010-00004. Pharmacoeconomics. 1999. PMID: 10345158 Review.
-
Cost effectiveness of therapies for atrial fibrillation. A review.Pharmacoeconomics. 2000 Oct;18(4):317-33. doi: 10.2165/00019053-200018040-00002. Pharmacoeconomics. 2000. PMID: 15344302 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
